Nu-Med Plus, Inc. (NUMD)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 Q2 '16: 0 Q3 '16: 0 Q4 '16: 0 Q1 '17: 0 Q2 '17: 0 Q3 '17: 0 Q4 '17: 0 Q1 '18: 0 Q2 '18: 0 Q3 '18: 0 Q4 '18: 0 Q1 '19: 0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q1 '20: 0 Q2 '20: 0 Q3 '20: 0 Q4 '20: 0 Q1 '21: 0 Q3 '16 Q2 '17 Q1 '18 Q4 '18 Q3 '19 Q2 '20 Q1 '21

Gross Profit TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income TTM

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '20: -1.7M Q4 '20: -2M Q1 '21: -2.2M Q2 '21: -1.5M Q3 '21: -1.2M Q4 '21: -839.4K Q1 '22: -542.4K Q2 '22: -348.4K Q3 '22: -288.1K Q4 '22: -182.2K Q1 '23: -149.5K Q2 '23: -114.5K Q3 '23: -71.6K Q4 '23: -120.5K Q1 '24: -114.1K Q2 '24: -107.1K Q3 '24: -109.4K Q4 '24: -63.3K Q1 '25: -61.5K Q2 '25: -55.8K Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Net Income TTM

-2.4M -1.6M -800K 0 800K 1.6M 2.4M Q3 '20: -1.7M Q4 '20: -2M Q1 '21: -2.2M Q2 '21: -1.5M Q3 '21: -1.2M Q4 '21: -830.1K Q1 '22: -530K Q2 '22: -345.4K Q3 '22: -285.1K Q4 '22: -130.2K Q1 '23: -101.7K Q2 '23: -68K Q3 '23: -26.3K Q4 '23: -125.5K Q1 '24: -119.1K Q2 '24: -112.1K Q3 '24: -114.4K Q4 '24: -68.3K Q1 '25: -66.5K Q2 '25: -60.8K Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

Cost of Revenue TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow TTM

-750K -500K -250K 0 250K 500K 750K Q2 '19: -653.5K Q3 '19: -586K Q4 '19: -567.3K Q1 '20: -415.8K Q2 '20: -442.7K Q3 '20: -468.2K Q4 '20: -414.8K Q1 '21: -398.9K Q2 '21: -317.9K Q3 '21: -257.9K Q4 '21: -206.8K Q1 '22: -139.7K Q2 '22: -75.8K Q3 '22: -34.2K Q4 '22: -38.5K Q1 '23: -46.5K Q2 '23: -67K Q3 '23: -86.5K Q4 '23: -66.4K Q1 '24: -46.7K Q3 '19 Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24

Free Cash Flow TTM

-210K -140K -70K 0 70K 140K 210K Q4 '12: -123K Q1 '13: -129.6K Q2 '13: -125.3K Q3 '13: -138.3K Q4 '13: -169.4K Q1 '14: -177.2K Q2 '14: -186.6K Q3 '14: -182K Q4 '14: -159.4K Q4 '12 Q2 '13 Q4 '13 Q2 '14 Q4 '14

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q1 '19: 41.5M Q2 '19: 45.3M Q3 '19: 46M Q1 '20: 46.6M Q2 '20: 47.3M Q3 '20: 50.3M Q1 '21: 79.3M Q2 '21: 79.3M Q1 '22: 79.3M Q2 '22: 79.3M Q3 '22: 79.7M Q1 '23: 81.3M Q2 '23: 81.3M Q3 '23: 81.3M Q1 '24: 83.5M Q3 '24: 81.3M Q1 '25: 83.5M Q2 '25: 83.5M Q1 '26: 83.5M Q2 '26: 83.5M Q2 '19 Q2 '20 Q2 '21 Q3 '22 Q3 '23 Q1 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.04 -0.03 -0.01 0.00 0.01 0.03 0.04 Q3 '20: -0.03 Q4 '20: -0.04 Q1 '21: -0.04 Q2 '21: -0.02 Q3 '21: -0.01 Q4 '21: 0.00 Q1 '22: 0.00 Q2 '22: 0.00 Q3 '22: 0.00 Q4 '22: 0.00 Q1 '23: 0.00 Q2 '23: 0.00 Q3 '23: 0.00 Q4 '23: 0.00 Q1 '24: 0.00 Q2 '24: 0.00 Q3 '24: 0.00 Q4 '24: 0.00 Q1 '25: 0.00 Q2 '25: 0.00 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23 Q3 '24 Q2 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.